

AMENDMENTS TO THE DRAWINGS:

The attached sheet of drawing includes Figure 1.

REMARKS

Claims 39-54 are pending. Claims 39 and 52 have been amended to clarify that SEQ ID NO:32 is used for numbering. SEQ ID NO:32 was added to the Sequence Listing, and corresponds to the third sequence of Figure 1. New claims 53 and 54 are added and are supported by the Table on page 41.

This application contains a Sequence Listing. Applicants enclose a computer-readable form of the Sequence Listing. The content of the paper copy of the Sequence Listing and of the computer readable form is the same. The Sequence Listing has been amended to include the sequences from Figure 1.

The specification has been amended to include appropriate sequence identifiers.

The specification has been amended to include Figure 1. Figure 1, which is referenced in the specification, was not included with the application at the time of filing. No new matter is added as Figure 1 is taken from parent application USSN 09/856,819, which was fully incorporated by reference into the present application.

The specification has been amended to remove the http sites (page 7), properly designate the trademarks (Page 17), and correct a number of typographical errors (page 27).

The Brief Description of the Drawings has been amended to refer to the sequence identifiers.

No new matter is added and entry of the amendments is respectfully requested.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: June 27, 2007

/Jason Garbell, Reg. # 44116/
Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212)840-0097